bexarotene has been researched along with Alzheimer Disease in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 36 (87.80) | 24.3611 |
| 2020's | 5 (12.20) | 2.80 |
| Authors | Studies |
|---|---|
| Karki, P; Mafimoghaddam, S; Orlova, EV; Orman, MA; Sherman, MB; Vekilov, PG; Xu, Y | 1 |
| Guo, J; Jin, G; Li, P; Liu, Y; Shao, Q; Shi, P; Wang, P; Yang, P; Yin, Y; Zhao, Y | 1 |
| Arboleda, G; Báez, T; Bustos-Rangel, A; Cardona-Gómez, GP; Múnera, A; Muñoz-Cabrera, JM; Niño, A; Sandoval-Hernández, AG | 1 |
| Hacioglu, C; Kanbak, G; Kar, F | 1 |
| Chia, S; Habchi, J; Horne, RI; Knowles, TPJ; Ruggeri, FS; Vendruscolo, M | 1 |
| Arboleda, G; Sandoval-Hernández, AG; Santos-Gil, DF | 1 |
| Casali, BT; Landreth, GE; Reed-Geaghan, EG | 1 |
| Abbasi, M; Chitranshi, N; Chung, R; Dheer, Y; Graham, SL; Gupta, V; Mirzaei, M; You, Y | 1 |
| Chen, C; Chen, G; Chi, T; Du, F; Gao, J; Guo, X; Ji, X; Jiang, W; Lang, H; Liu, D; Liu, P; Qiu, S; Tang, X; Xu, J; Yang, Y; Yuan, C; Zhou, Q; Zhou, X; Zou, L | 1 |
| Agujetas, VR; Albrecher, NM; Carmen Kober, A; Colell, A; de Dios, C; Fanaee-Danesh, E; Gali, CC; Madeo, F; Malle, E; Manavalan, APC; Panzenboeck, U; Reiter, M; Stracke, A; Sun, Y; Tadic, J; Tam-Amersdorfer, C; Zandl-Lang, M | 1 |
| Gerges, M; Martín-Maestro, P; Martinez, H; Noggle, S; Paquet, D; Sproul, A; Starkov, AA | 1 |
| Mahadevan, L; Michaels, TCT; Weber, CA | 1 |
| Batool, A; Bibi, N; Kamal, MA; Rizvi, SMD | 1 |
| Royall, DR | 1 |
| Allard, JS; LaClair, KD; Lee, DL; Manaye, KF; Savonenko, AV; Troncoso, JC; Wong, PC | 1 |
| Aicardi, G | 1 |
| Garner, JD | 1 |
| Bu, G; Dong, Q; Fu, Y; Kanekiyo, T; Liu, CC; Nielsen, HM; Shinohara, M; Zhao, J | 1 |
| Bomben, V; Cramer, P; Holth, J; Landreth, G; Noebels, J; Reed, J | 1 |
| Nathans, J; Williams, J; Wu, H | 1 |
| Ben Aissa, M; Collins, NC; Koster, KP; LaDu, MJ; Lee, SH; Luo, J; Tai, LM; Thatcher, GRJ; Wang, YT | 1 |
| Balducci, C; Forloni, G; Grigoli, E; La Vitola, P; Micotti, E; Paladini, A; Richardson, JC; Tolomeo, D | 1 |
| Goduni, E; Jay, T; Lamb, BT; Landreth, GE; Malm, T; Mariani, MM; Quigley, C; Ransohoff, RM; Savage, JC | 1 |
| Barbour, B; Guo, JP; Hanna, D; Hobson, P; Jeggo, R; Kim, EM; Lyons, T; McGeer, EG; McGeer, PL; Meara, JR; O'Hare, E; Page, D; Palmer, P; Spanswick, D; Walczak, JS | 1 |
| Casali, BT; Corona, AW; Ghosal, K; Karlo, JC; Landreth, GE; Mariani, MM | 1 |
| Casali, BT; Corona, AW; Kodoma, N; Landreth, GE | 1 |
| Belyaev, ND; Nalivaeva, NN; Turner, AJ | 1 |
| Dricot, L; Hanseeuw, B; Ivanoiu, A; Lhommel, R; Maloteaux, JM; Octavea, JN; Pierrot, N; Quenon, L; Sindic, C | 1 |
| Bena, J; Cummings, JL; Devous, M; Heaney, C; Joshi, A; Kinney, JW; Moll-Tudla, J; Pontecorvo, M; Tang, A; Zhong, K | 1 |
| Blanco-Gandía, M; Bonet-Costa, V; Borras, C; Garcia-Tarraga, P; Garcia-Verdugo, JM; Herranz-Pérez, V; Inglés, M; Mas-Bargues, C; Miñarro, J; Rodriguez-Arias, M; Viña, J | 1 |
| Arosio, P; Chia, S; Cohen, SI; Costa, AR; Dobson, CM; Habchi, J; Joshi, P; Knowles, TP; Linse, S; Müller, MB; Nollen, EA; Perni, M; Vendruscolo, M; Yagi-Utsumi, M | 1 |
| Belfort, G; Isaacson, D; Rosenthal, J | 1 |
| Beg, MA; Mirza, Z | 1 |
| Casali, B; Jay, TR; Lamb, R; Landreth, GE; Malm, T; Mariani, MM; Medarametla, L; Neilson, L | 1 |
| Brunden, KR; Casali, BT; Cirrito, JR; Cramer, PE; Goebel, WD; James, MJ; Karlo, JC; Landreth, GE; Lee, CY; Restivo, JL; Wesson, DW; Wilson, DA; Zinn, AE | 1 |
| Strittmatter, WJ | 1 |
| Nau, JY | 1 |
| Gross, M | 1 |
| Hull, SC; Lowenthal, J; Pearson, SD | 1 |
| LaFerla, FM | 1 |
1 review(s) available for bexarotene and Alzheimer Disease
| Article | Year |
|---|---|
The novel function of bexarotene for neurological diseases.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Bexarotene; Humans; Retinoid X Receptors; Tetrahydronaphthalenes | 2023 |
1 trial(s) available for bexarotene and Alzheimer Disease
| Article | Year |
|---|---|
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Apolipoproteins E; Bexarotene; Double-Blind Method; Female; Humans; Male; Middle Aged; Peptide Fragments; Positron-Emission Tomography; Retinoid X Receptors; Tetrahydronaphthalenes; Treatment Outcome | 2016 |
39 other study(ies) available for bexarotene and Alzheimer Disease
| Article | Year |
|---|---|
Suppression of amyloid-β fibril growth by drug-engineered polymorph transformation.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Bexarotene; Peptide Fragments; Plaque, Amyloid; Rats | 2022 |
Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer´s disease.
Topics: Alzheimer Disease; Animals; Apolipoproteins E; Bexarotene; DNA-Binding Proteins; Female; Gliosis; Hippocampus; Male; Maze Learning; Mice; Nerve Tissue Proteins; Neuroglia; Neuronal Plasticity; Neuroprotective Agents; Synaptic Transmission | 2019 |
Ex Vivo Investigation of Bexarotene and Nicotinamide Function as a Protectıve Agent on Rat Synaptosomes Treated with Aβ(1-42).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Bexarotene; Brain; Male; Neuroprotective Agents; Niacinamide; Oxidative Stress; Peptide Fragments; Poly (ADP-Ribose) Polymerase-1; PPAR gamma; Rats, Wistar; Signal Transduction; Sirtuin 1; Synaptosomes | 2021 |
Infrared nanospectroscopy reveals the molecular interaction fingerprint of an aggregation inhibitor with single Aβ42 oligomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Bexarotene; Drug Discovery; Feasibility Studies; Humans; Hydrogen Bonding; Kinetics; Microscopy, Atomic Force; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Recombinant Proteins; Single Molecule Imaging; Spectrophotometry, Infrared; Structure-Activity Relationship; Vibration | 2021 |
Retinoid X receptor activation promotes re-myelination in a very old triple transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Bexarotene; Cell Proliferation; Cerebral Cortex; Female; Hippocampus; Male; Mice; Mice, Inbred C57BL; Myelin Sheath; Neuroprotective Agents; Oligodendroglia; Presenilin-1; Retinoid X Receptors; tau Proteins | 2021 |
Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Bexarotene; Cells, Cultured; Cognition; Cognition Disorders; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Transgenic; Peptide Fragments; Plaque, Amyloid; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors | 2018 |
Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; bcl-Associated Death Protein; Bexarotene; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Endoplasmic Reticulum Stress; Humans; Male; Mice, Inbred C57BL; Neuroprotection; Neurotoxicity Syndromes; Receptor, trkB; Retinoid X Receptors; Up-Regulation | 2018 |
OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Bexarotene; Body Weight; CD36 Antigens; Cerebral Cortex; Cognitive Dysfunction; Hippocampus; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Neuronal Plasticity; Peptide Fragments; Presenilin-1 | 2019 |
Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
Topics: ADAM10 Protein; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; Bexarotene; Blood-Brain Barrier; Cholesterol; Down-Regulation; Endothelial Cells; Female; Mice; Mice, Inbred C57BL; Mice, Transgenic; Probucol; Protective Agents; Swine; Xanthophylls | 2019 |
Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer's Disease iPSC-Derived Neural Stem Cells.
Topics: Alzheimer Disease; Autophagy; Bexarotene; DNA, Mitochondrial; Humans; Induced Pluripotent Stem Cells; Mitochondria; Mitophagy; Neural Stem Cells; Presenilin-1 | 2019 |
Optimal control strategies for inhibition of protein aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Bexarotene; Caenorhabditis elegans; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Kinetics; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Time Factors | 2019 |
Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β Peptide Aggregation: Repurposing Via Neuroinformatics Approach.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Bexarotene; Drug Repositioning; Humans; Peptide Fragments | 2019 |
The "ethics" of evidence are not evidence of ethics.
Topics: Alzheimer Disease; Animals; Anticarcinogenic Agents; Bexarotene; Clinical Trials as Topic; Disease Models, Animal; Drug Approval; Ethics, Medical; Humans; Off-Label Use; Tetrahydronaphthalenes; United States | 2013 |
Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.
Topics: Alzheimer Disease; Animals; Anticarcinogenic Agents; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Behavior, Animal; Bexarotene; Blotting, Western; Disease Models, Animal; Female; Male; Memory; Mice; Mice, Mutant Strains; Plaque, Amyloid; Tetrahydronaphthalenes | 2013 |
New hope from an old drug: fighting Alzheimer's disease with the cancer drug bexarotene (targretin)?
Topics: Alzheimer Disease; Animals; Bexarotene; Drug Evaluation, Preclinical; Humans; Mice; Reproducibility of Results; Retinoid X Receptors; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2013 |
From the editor.
Topics: Alzheimer Disease; Animals; Antineoplastic Agents; Bexarotene; Clinical Trials, Phase I as Topic; Humans; Mice; Tetrahydronaphthalenes | 2014 |
Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.
Topics: Alleles; Alzheimer Disease; Animals; Anticarcinogenic Agents; Apolipoproteins E; Astrocytes; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Bexarotene; Brain; Cell Line, Transformed; Humans; Lipoproteins; Lipoylation; Mice; Mice, Transgenic; Nerve Tissue Proteins; Receptors, Retinoic Acid; Retinoid X Receptors; Tetrahydronaphthalenes; Tretinoin | 2014 |
Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Bexarotene; Cerebral Cortex; Cognition; Disease Models, Animal; Electroencephalography; Epilepsy; Hippocampus; Memory; Mice; Retinoid X Receptors; Tetrahydronaphthalenes | 2014 |
Complete morphologies of basal forebrain cholinergic neurons in the mouse.
Topics: Alkaline Phosphatase; Alzheimer Disease; Animals; Axons; Basal Forebrain; Bexarotene; Cell Line; Cholinergic Neurons; Disease Models, Animal; Disease Progression; Hippocampus; Image Processing, Computer-Assisted; Mice; Mice, Knockout; Microscopy, Confocal; Tetrahydronaphthalenes | 2014 |
Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Bexarotene; Disks Large Homolog 4 Protein; Drug Evaluation, Preclinical; Genotype; Guanylate Kinases; Humans; Lipoproteins; Liver; Male; Membrane Proteins; Mice, Inbred C57BL; Mice, Transgenic; Nicotinic Acids; Organ Size; Peptide Fragments; Retinoid X Receptors; Solubility; Tetrahydronaphthalenes | 2014 |
The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.
Topics: Alzheimer Disease; Animals; Apolipoproteins E; Bexarotene; Brain; Disease Models, Animal; Female; Liver X Receptors; Maze Learning; Mice; Mice, Transgenic; Microglia; Orphan Nuclear Receptors; Retinoid X Receptors; Tetrahydronaphthalenes; Treatment Failure | 2015 |
Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Axl Receptor Tyrosine Kinase; Benzoates; Benzylamines; Bexarotene; c-Mer Tyrosine Kinase; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Leukocyte Common Antigens; Macrophages; Male; Membrane Glycoproteins; Mice; Microglia; Myeloid Cells; Phagocytosis; Pioglitazone; Plaque, Amyloid; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones | 2015 |
Lack of support for bexarotene as a treatment for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Bexarotene; CA1 Region, Hippocampal; CHO Cells; Conditioning, Operant; Cricetulus; Culture Media, Conditioned; Disease Models, Animal; Excitatory Postsynaptic Potentials; Long-Term Potentiation; Male; Maze Learning; Mice; Mice, Transgenic; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 2016 |
Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Bexarotene; Brain; Cells, Cultured; Disease Models, Animal; Docosahexaenoic Acids; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Tetrahydronaphthalenes | 2015 |
ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; Bexarotene; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hippocampus; Humans; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Knockout; Polymerase Chain Reaction; Presenilin-1; Tetrahydronaphthalenes | 2016 |
New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Bexarotene; Brain; Cell Line, Tumor; Epigenesis, Genetic; Humans; Insulysin; Neprilysin; Protein Isoforms; Protein Structure, Tertiary; Retinoid X Receptors; RNA, Messenger; Tetrahydronaphthalenes | 2016 |
Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Amyloidogenic Proteins; Bexarotene; Biomarkers; Cognition Disorders; Humans; Male; Mental Recall; Neuropsychological Tests; Receptors, Retinoic Acid; tau Proteins; Tetrahydronaphthalenes | 2016 |
Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; Astrocytes; Avoidance Learning; Bexarotene; Brain; Cells, Cultured; Disease Models, Animal; Female; Genistein; Habituation, Psychophysiologic; Maze Learning; Mice, Inbred C57BL; Mice, Transgenic; Neuroprotective Agents; Nootropic Agents; Olfactory Perception; Plaque, Amyloid; PPAR gamma; Recognition, Psychology; Tetrahydronaphthalenes | 2016 |
An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Antineoplastic Agents; Bexarotene; Caenorhabditis elegans; Drug Discovery; Humans; In Vitro Techniques; Kinetics; Models, Animal; Molecular Sequence Data; Peptide Fragments; Protein Multimerization; Recombinant Proteins; Taurine; Tetrahydronaphthalenes | 2016 |
Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticarcinogenic Agents; Bexarotene; Brain; Computer Simulation; Disease Models, Animal; Mice; Models, Theoretical; Tetrahydronaphthalenes | 2016 |
Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Bexarotene; Computational Biology; Humans; Hydrogen Bonding; Molecular Docking Simulation; Neuroprotective Agents; Protein Binding; Retinoid X Receptors; Tetrahydronaphthalenes | 2017 |
Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Bexarotene; Biomarkers; Cell Survival; Cytokines; Disease Models, Animal; Female; Gliosis; Glutamic Acid; Habituation, Psychophysiologic; Hippocampus; Inflammation; Male; Membrane Transport Proteins; Memory; Mice, Transgenic; Neurons; Neurotoxins; Olfactory Bulb; Plaque, Amyloid; Receptors, LDL; Retinoid X Receptors; Synapses; Tetrahydronaphthalenes | 2017 |
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Animals; Apolipoproteins E; Astrocytes; Behavior, Animal; Bexarotene; Brain; Disease Models, Animal; Extracellular Fluid; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Molecular Targeted Therapy; Odorants; Olfactory Pathways; Orphan Nuclear Receptors; Phagocytosis; Plaque, Amyloid; PPAR gamma; Retinoid X Receptors; Tetrahydronaphthalenes | 2012 |
Medicine. Old drug, new hope for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; Bexarotene; Brain; Male; Tetrahydronaphthalenes | 2012 |
[Alzheimer disease: the temptation coming from off-label use].
Topics: Alzheimer Disease; Animals; Antineoplastic Agents; Bexarotene; Drug Approval; Drug Repositioning; Exploratory Behavior; Guideline Adherence; Humans; Mass Media; Mice; Off-Label Use; Plaque, Amyloid; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
Latest Alzheimer's research: some rays of hope.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Bexarotene; Biomedical Research; Cognition; Health Status; Humans; Patient Education as Topic; Plaque, Amyloid; Tetrahydronaphthalenes; United States | 2012 |
Understanding amyloid and Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Bexarotene; Brain; Central Nervous System Agents; Humans; Plaque, Amyloid; Tetrahydronaphthalenes | 2012 |
The ethics of early evidence--preparing for a possible breakthrough in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anticarcinogenic Agents; Bexarotene; Clinical Trials as Topic; Disease Models, Animal; Drug Approval; Ethics, Medical; Humans; Mice; Off-Label Use; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2012 |
Preclinical success against Alzheimer's disease with an old drug.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; Bexarotene; Humans; Mice; Mice, Transgenic; Plaque, Amyloid; Retinoid X Receptors; Tetrahydronaphthalenes | 2012 |